HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Guidances Will Address NDI “Misperceptions,” Energy Drinks

This article was originally published in The Tan Sheet

Executive Summary

FDA is working on two guidances that will affect the supplement industry: a revised new dietary ingredient notification draft guidance and a drinks guidance that will address whether energy drinks are supplements or conventional foods, CFSAN director Michael Landa said.

You may also be interested in...



FDA Should Accept Industry’s Grandfathered Ingredient Lists – NPA

FDA “Undercuts” NDI Guidance Opposition With Compliance Cost Estimate – CRN

OMB approves FDA’s estimate as the official measure for the supplement industry’s anticipated burden in complying with the NDI notification regulation.

FDA Supplement Beverage Guidance May Open Can Of Regulatory Worms

An FDA draft guidance has the potential to make defining a beverage as a dietary supplement much tougher

Topics

Latest News
UsernamePublicRestriction

Register

RS125067

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel